SCHEDULE 13G
Statement of Beneficial Ownership
SELLAS Life Sciences Group, Inc. Filed Acc 0002100119-26-001315
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Vanguard Capital Management | 9,666,278 | 5.19% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-10 SCHEDULE 13G · STATE STREET CORPORATION 5.1%
- 2026-10-27 SCHEDULE 13G/A · BlackRock, Inc. 7.9%
- 2026-08-07 SCHEDULE 13G · STATE STREET CORPORATION 7%
- 2026-07-31 SCHEDULE 13G · Vanguard Capital Management 5.19%
- 2026-04-24 SCHEDULE 13G/A · BlackRock, Inc. 6.8%
- 2026-03-27 SCHEDULE 13G/A · The Vanguard Group 0%
- 2026-02-17 SCHEDULE 13G/A · Anson Funds Management LP 4.9%
- 2026-01-30 SCHEDULE 13G/A · Highbridge Capital Management, LLC 3.7%
- 2025-11-14 SCHEDULE 13G · Anson Funds Management LP 5.7%
- 2025-10-17 SCHEDULE 13G · BlackRock, Inc. 5.4%
- 2025-08-14 SCHEDULE 13G/A · Anson Funds Management LP 4.9%
- 2025-07-29 SCHEDULE 13G · The Vanguard Group 6.70%
- 2025-05-15 SCHEDULE 13G · Anson Funds Management LP 8.3%
- 2024-11-08 SC 13G/A · Highbridge Capital Management, LLC 9.90%
- 2024-02-07 SC 13G · Highbridge Capital Management, LLC 6.5%
- 2021-02-16 SC 13G/A · CVI Investments, Inc. 2.7%
- 2021-02-12 SC 13G/A · Globis Capital Partners, L.P. 1.2%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…